Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 7, 2014, Pages 1795-1806

  Zhu, Fengcai ^a   Li, Juan ^b   Hu, Yuemei ^a   Zhang, Xiang ^a   Yang, Xiaoping ^c   Zhao, Hui ^b   Wang, Junzhi ^b   Yang, Jianguo ^a   Xia, Guodong ^c   Dai, Qinyong ^d   Tang, Haiwen ^e   Suryakiran, Pemmaraju ^f   Datta, Sanjoy K ^g   Descamps, Dominique ^g   Bi, Dan ^g   Struyf, Frank ^g  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^c SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d MVA Hong Kong Ltd   (Hong Kong)

^e GLAXOSMITHKLINE   (China)

^f GlaxoSmithKline Pharmaceuticals Ltd   (India)

^g GSK   (Belgium)

Author keywords

Cervical cancer; China; Female; HPV 16 18 AS04 adjuvanted vaccine; Human papillomavirus; Immunogenicity; Safety

Indexed keywords

VIRUS ANTIBODY; WART VIRUS VACCINE; ALUMINUM HYDROXIDE; ASO4 MIXTURE; LIPID A;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILD; CHINESE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNOGENICITY; LIMIT OF DETECTION; MIDDLE AGED; MYALGIA; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROCONVERSION; SERODIAGNOSIS; VIRUS STRAIN; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANTIBODIES, VIRAL; ASIAN CONTINENTAL ANCESTRY GROUP; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CHINA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LIPID A; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908542177     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28702     Document Type: Article

References (45)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. Accessed on 17 December 2013.
2. Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer 2012; 130:641-52; PMID:21387308; http://dx.doi.org/10.1002/ijc.26042
3. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184:9-13; PMID:1651607; http://dx.doi.org/10.1016/0042-6822(91)90816-T
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9; PMID:10451482; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1〈12::AIDPATH431〉3.0.CO;2-F
5. Bao YP, Li N, Smith JS, Qiao YL. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS 2008; 19:106-11; PMID:18334063; http://dx.doi.org/10.1258/ijsa.2007.007113
6. Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, Schmidt JE, Wang P, Liu YL, Li LK, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control 2009; 20:1705-13; PMID:19705288; http://dx.doi.org/10.1007/s10552-009-9422-z
7. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128:927-35; PMID:20473886; http://dx.doi.org/10.1002/ijc.25396
8. Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X, Zhang YJ, Pan QJ, Zhao FH, Yu JX, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: Results from a randomised controlled trial. Int J Cancer 2014; (Forthcoming); PMID:24740596; http://dx.doi.org/10.1002/ijc.28897
9. Castellsagué X, Schneider A, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 2009; 115(Suppl):S15-23; PMID:19819540; http://dx.doi.org/10.1016/j.ygyno.2009.09.021
10. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, et al.; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65; PMID:15541448; http://dx.doi.org/10.1016/S0140-6736(04)17398-4
11. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsagué X, et al.; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi.org/10.1016/S0140-6736(07)60946-5
12. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D, et al.; HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009; 27:581-7; PMID:19022320; http://dx.doi.org/10.1016/j.vaccine.2008.10.088
13. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, et al.; HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40:564-71; PMID:17531764; http://dx.doi.org/10.1016/j.jadohealth.2007.02.015
14. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009; 5:332-40; PMID:19221517; http://dx.doi.org/10.4161/hv.5.5.7211
15. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006; 24(Suppl 3):S3, 106-13; PMID:16949996; http://dx.doi.org/10.1016/j.vaccine.2006.05.110
16. Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010; 8:260-70; PMID:20833377; http://dx.doi.org/10.1016/j.chom.2010.08.003
17. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425-34; PMID:18948732; http://dx.doi.org/10.4161/hv.4.6.6912
18. Schwarz TF, Kocken M, Petäjä T, Einstein MH, Spaczynski M, Louwers JA, Pedersen C, Levin M, Zahaf T, Poncelet S, et al. Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccin 2010; 6:1054-61; PMID:21157180; http://dx.doi.org/10.4161/hv.6.12.13399
19. Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. PLoS One 2013; 8:e61825; PMID:23650505; http://dx.doi.org/10.1371/journal.pone.0061825
20. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
21. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, et al.; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99; PMID:22075171; http://dx.doi.org/10.1016/S1470-2045(11)70286-8
22. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G; HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-55; PMID:16631880; http://dx.doi.org/10.1016/S0140-6736(06)68439-0
23. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, et al.; GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-85; PMID:19962185; http://dx.doi.org/10.1016/S0140-6736(09)61567-1
24. De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, Sanchez N, Schuind A. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28:6247-55; PMID:20643092; http://dx.doi.org/10.1016/j.vaccine.2010.07.007
25. Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8:390-7; PMID:22327492; http://dx.doi.org/10.4161/hv.18865
26. Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer 2010; 20:847-55; PMID:20606533; http://dx.doi.org/10.1111/IGC.0b013e3181da2128
27. Konno R, Dobbelaere KO, Godeaux OO, Tamura S, Yoshikawa H. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7. Int J Gynecol Cancer 2009; 19:905-11; PMID:19574783; http://dx.doi.org/10.1111/IGC.0b013e3181a23c0e
28. Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial. Int J Gynecol Cancer 2010; 20:404-10; PMID:20375805; http://dx.doi.org/10.1111/IGC.0b013e3181d373a5
29. GlaxoSmithKline. Study to evaluate the efficacy of the human papillomavirus vaccine in healthy adult women of 26 years of age and older. In: ClinicalTrials.gov [Internet]. Bethseda (MD): National Library of Medicine (US). 2000- [cited 2013 Dec 14]. Available from: http://www.clinicaltrials.gov/show/NCT00294047. NLM Identifier: NCT00294047.
30. Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, Descamps DJ, Bock HL; Indian HPV Vaccine Study Group. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res 2010; 36:123-32; PMID:20178538; http://dx.doi.org/10.1111/j.1447-0756.2009.01167.x
31. Sow PS, Watson-Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J, Bousso K, Kavishe B, Andreasen A, Toure M, et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women. J Infect Dis 2013; 207:1753-63; PMID:23242542; http://dx.doi.org/10.1093/infdis/jis619
32. Petäjä T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, Lehtinen M, Descamps D. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 2011; 129:2147-57; PMID:21190190; http://dx.doi.org/10.1002/ijc.25887
33. Medina DM, Valencia A, de Velasquez A, Huang LM, Prymula R, García-Sicilia J, Rombo L, David MP, Descamps D, Hardt K, et al.; HPV-013 Study Group. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health 2010; 46:414-21; PMID:20413076; http://dx.doi.org/10.1016/j.jadohealth.2010.02.006
34. Schwarz TF, Huang LM, Medina DM, Valencia A, Lin TY, Behre U, Catteau G, Thomas F, Descamps D. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health 2012; 50:187-94; PMID:22265115; http://dx.doi.org/10.1016/j.jadohealth.2011.11.004
35. David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009; 115(Suppl):S1-6; PMID:19217149; http://dx.doi.org/10.1016/j.ygyno.2009.01.011
36. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, Poncelet SM, Catteau G, Thomas F, Descamps D. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccin 2011; 7:958-65; PMID:21892005; http://dx.doi.org/10.4161/hv.7.9.15999
37. Coseo S, Porras C, Hildesheim A, Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Gonzalez P, Wang SS, Sherman ME, et al.; Costa Rica HPV Vaccine Trial (CVT) Group. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica. Sex Transm Dis 2010; 37:706-14; PMID:20661178; http://dx.doi.org/10.1097/OLQ.0b013e3181e1a2c5
38. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, Kiviat N, Galloway DA. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996; 174:927-36; PMID:8896492; http://dx.doi.org/10.1093/infdis/174.5.927
39. Tiggelaar SM, Lin MJ, Viscidi RP, Ji J, Smith JS. Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. J Adolesc Health 2012; 50:110-31; PMID:22265107; http://dx.doi.org/10.1016/j.jadohealth.2011.10.010
40. Li J, Huang R, Schmidt JE, Qiao YL. Epidemiological features of Human Papillomavirus (HPV) infection among women living in Mainland China. Asian Pac J Cancer Prev 2013; 14:4015-23; PMID:23991946; http://dx.doi.org/10.7314/APJCP.2013.14.7.4015
41. Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, et al.; HPV PATRICIA Study Group. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012; 131:106-16; PMID:21858807; http://dx.doi.org/10.1002/ijc.26362
42. Kim YJ, Kim KT, Kim JH, Cha SD, Kim JW, Bae DS, Nam JH, Ahn WS, Choi HS, Ng T, et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. J Korean Med Sci 2010; 25:1197-204; PMID:20676333; http://dx.doi.org/10.3346/jkms.2010.25.8.1197
43. Ngan HY, Cheung AN, Tam KF, Chan KK, Tang HW, Bi D, Descamps D, Bock HL. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med J 2010; 16:171-9; PMID:20519752
44. Vaccarella S, Franceschi S, Clifford GM, Touzé A, Hsu CC, de Sanjosé S, Pham TH, Nguyen TH, Matos E, Shin HR, et al.; IARC HPV Prevalence Surveys Study Group. Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 2010; 19:2379-88; PMID:20826835; http://dx.doi.org/10.1158/1055-9965.EPI-10-0336
45. Li J, Kang LN, Qiao YL. Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev 2011; 12:1149-53; PMID:21875257